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 Abstract 
 Background: Human epididymis protein 4 (HE4) is described 
as a useful new biomarker in ovarian cancer. As HE4 is nei-
ther tumor nor organ specifi c, we intensively investigated 
the occurrence of this protein in female and male patients 
with various benign and malignant diseases in order to avoid 
misinterpretation and to identify potential additional clinical 
relevance. 
 Methods: We retrospectively investigated HE4 
(ARCHITECT  ®  , Abbott Diagnostics, US) in the sera of 205 
healthy individuals, 654 patients with benign disorders and 
720 patients with cancer before initial treatment. 
 Results: The lowest concentrations of HE4 were observed 
in healthy men (median 26.2 pmol/L) followed by healthy 
women (median 40.4 pmol/L). In benign diseases, highest 
HE4 concentrations were seen in both women and men with 
renal failure (women, median 1041 pmol/L; men, median 1368 
pmol/L). In women, the highest HE4 levels in malignant dis-
eases were observed in ovarian cancer (median 242 pmol/l), 
whereas the highest HE4 concentrations in men occurred in 
lung cancer (median 89.2 pmol/L). The area under the curve 
(AUC) of HE4 in women was highest in ovarian cancer and 
borderline tumors as compared to benign gynecological dis-
orders (88.9 % ), with a sensitivity of 67.4 % at 95 % specifi city. 
Also, signifi cantly elevated concentrations of HE4 with refer-
ence to the respective group of benign diseases were observed 
in uterus corpus and breast cancer as well as in lung cancer 
for men and women. 
 Conclusions: HE4 has the highest relevance in ovarian can-
cer but can be elevated in a variety of benign and malignant 
diseases. 
 Keywords:  benign diseases;  HE4;  malignant diseases;  tumor 
marker. 
 Introduction 
 Ovarian cancer is the leading cause of death among gyne-
cologic malignancies. Due to the lack of diagnostic tools 
for early detection of ovarian cancer, the vast majority of 
patients are diagnosed when they have an advanced stage of 
disease. Thus, there is a need to detect ovarian cancer when 
it is suffi ciently small to be curable by existing therapies  (1) . 
Cancer antigen 125 (CA 125) in serum has a high sensitivity 
for ovarian cancer, but CA 125 levels are frequently elevated 
in women with benign gynecological diseases, resulting in 
a reduced specifi city of this marker, especially in premeno-
pausal women  (2, 3) . Therefore, there is a need for additional 
markers that can complement CA 125, both for early detection 
and differential diagnosis. One of the most promising new 
biomarkers is the human epididymis protein 4 (HE4). The 
HE4 gene encodes a WAP-type four disulphide core domain-
containing protein with a presumptive role in natural immu-
nity. HE4 gene expression is highest in normal human trachea 
and salivary gland, but also active in lung, prostate, pituitary 
gland, thyroid and kidney. Multiple studies have consistently 
identifi ed an upregulation of HE4 gene expression in carci-
nomas of the ovary  (4, 5) . Within a relatively short time it 
became evident that HE4 is also released signifi cantly into 
the blood by ovarian cancer and that this release offers an 
incremental diagnostic value in addition to CA 125 in ovar-
ian cancer  (6 – 16) . Intense gene expression studies on HE4 
revealed signifi cant expression and strong immunoreactivity 
in ovarian cancer, but also in some pulmonary, endometrial 
and breast adenocarcinomas as well as gastrointestinal and 
urological carcinomas. Thus, HE4 like all other biomarkers 
is not a tumor specifi c protein and, like the vast majority of 
biomarkers, also not organ specifi c. 
 We performed this study to analyze the release or of HE4 
into the blood by various benign and malignant diseases to 
reduce misinterpretations when applying biomarkers in diag-
nostic oncology like in ovarian cancer diagnostics and other 
tumor diseases. Therefore, we investigated samples from 
female and male healthy individuals and patients with benign 
and malignant diseases. 
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 Materials and methods 
 Controls and patients 
 We retrospectively evaluated the sera of 205 healthy individuals, 
654 patients with various benign disorders and 720 patients suffer-
ing from cancer. The sera were collected between January 1986 and 
April 2009. All serum samples had been obtained at primary diag-
nosis and had been stored at  – 80 ° C. A plot of HE4 values against 
storage time of the samples revealed no dependencies. 
 All 205 healthy individuals underwent an intense anamnesis and 
were apparently healthy when the blood samples were drawn as well 
as 6 months later when consecutive blood samples were drawn. In 
addition, they had no suspicious fi ndings in a broad profi le of blood 
and urine analyses. 
 The 654 patients suffering from benign diseases were distributed 
as follows (Table 1): the group of benign lung diseases (n = 50) con-
sisted of bronchial asthma, bronchitis, chronic obstructive pulmonary 
disease (COPD), pneumonia, and benign lung tumors. Benign gas-
trointestinal diseases (n = 82) mainly included hepatitis, cholangitis, 
cholelithiasis, cholestasis, liver cirrhosis, pancreatitis and liver ade-
nomas. For benign urological diseases, patients with benign hyperpla-
sia of the prostate (n = 21) as well as patients with renal failure (n = 33) 
were considered separately. The remaining benign urological diseases 
(n = 24) included renal cysts, voiding problems, hydronephrosis, renal 
and uretheral calculi and prostatitis. Table 2 shows the distribution of 
benign gynecological diseases (n = 396) in more detail. 
 All 720 patients with cancer underwent surgery and were histo-
morphologically diagnosed. The corresponding blood samples had 
been drawn before any treatment. The study was approved by the 
Local Ethical Committee. Informed consent was obtained from all 
patients participating in this study. In this retrospective evaluation, 
tumor marker levels were analyzed with reference to patient charac-
teristics and clinical data. 
 Serum analysis 
 HE4 was analyzed using the ARCHITECT  ®  system (Abbott 
Diagnostics, USA). The ARCHITECT assay for HE4 is a two-step 
immunoassay. In the fi rst step, sample and 2H5 anti-HE4 coated 
paramagnetic microparticles are combined. HE4 antigen then binds 
to the anti-HE4 coated microparticles. In the second step, 3D8 
anti-HE4 acridinium labeled conjugate is added to the HE4 assay. 
Chemiluminiscent reaction is measured in relative light units and 
directly refl ects HE4 concentrations in the serum samples. The 
limit of detection (LoD) of this assay is 0.3 pmol/L, and the limit of 
quantitation (LoQ) is 1.4 pmol/L. The within-run imprecision of the 
ARCHITECT HE4 assay for three controls and three pools covering 
the measuring range up to 1500 pmol/L varies between 3.1 % and 
4.9 % and the inter-assay imprecision between 4.5 % and 5.1 % (as 
indicated by the supplier). 
 Statistics 
 Statistical analysis was performed using SAS V9.2 (SAS Institute 
Inc., Cary, NC, USA). HE4 marker results are given as median, range 
and percentiles. HE4 concentrations were compared between groups 
using the Wilcoxon test. Dependency on age was tested using the 
general linear model (GLM) procedure for an overall p-value and 
the Ryan-Einot-Gabriel-Welsch multiple range test for assessing 
signifi cant differences between the age groups. Receiver operating 
characteristic (ROC) curves were assessed to refl ect the relationship 
between sensitivity and specifi city for HE4. They were compared 
by means of the areas under the curves (AUC) and additionally by 
sensitivities at a set specifi city of 95 % . 
 For showing extreme values of HE4 we defi ned the upper limit 
of the healthy population as three times the interquartile range and 
added this value to the upper quartiles of the distribution stratifi ed 
for gender and age ( < 50 and  ≥ 50 years). When applying this rule, 
the extreme values reached for women were 96 pmol/L for  < 50 
and 120 pmol/L for  > 50 years, for men 81 pmol/L  < 50 and 93 
pmol/L  > 50 years. Values above the upper limit in the respective age 
and gender group are plotted in decreasing order of HE4 values. 
 Results 
 HE4 in healthy individuals 
 The group of healthy individuals consisted of 109 women and 
96 men. 
 Figure  1 A demonstrates the HE4 concentrations of healthy 
women by age decades. The median age of healthy women 
was 38.4 years (range 21.5 – 80.0 years). Median values of 
HE4 increased with age from 33.5 pmol/L in women under 
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 Figure 1  Distribution of HE4 values in healthy women (A) and men (B). 
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30 years to 54.5 pmol/L in women over 60 years (overall 
p < 0.001). Differences were signifi cant between the group of 
women over 60 years and all other groups as well as between 
the group of women between 50 and 60 years and women 
younger than 30 years. 
 The median age of healthy men was 37.2 years (range 
21.5 – 80.0 years) and thus comparable to the age of healthy 
women (p = 0.811). Median HE4 concentrations in healthy 
men also increased with age (Figure 1B) from 22.6 pmol/L 
in men under 30 years to 38.4 pmol/L in men over 60 years 
(overall p < 0.001). Differences were signifi cant between the 
group of men over 60 years and the groups of men younger 
than 50 years, as well as between the group of men between 
50 and 60 years and men younger than 30 years. As HE4 con-
centrations in men were signifi cantly lower than in women, 
we analyzed HE4 levels for men and women separately in 
our study. 
 HE4 in benign and malignant diseases 
 The distribution of HE4 values in women and men with 
benign diseases is described in Table  1 . 
 Both in women and men, the highest HE4 values were 
observed in patients with renal failure. With the exception of 
renal failure, median levels of HE4 in women with benign 
diseases were comparable to the median of healthy women, 
however with a broad range of values especially for benign 
gastrointestinal and benign gynecological diseases. In benign 
gastrointestinal diseases, highest HE4 values were seen in 
liver cirrhosis and cholangitis. In benign gynecological dis-
eases, the highest single values were observed for women 
with leiomyoma, while women with infl ammatory diseases 
and bleeding disorders had the highest median values of HE4 
(Table  2 ). 
 The group of bleeding disorders includes 12 cases of post-
menopausal bleeding, six women with menometrorrhagia, 
fi ve cases of perimenopausal bleeding, two patients suffering 
from dysmenorrhea, one woman with serometra, one patient 
with endometrial polyp, one case of hematocolpos in uterus 
duplex, one case of suspicious endometrium, two cases of 
endometrial hyperplasia and one bleeding disorder of a patient 
with a persistent high  β -HCG value. Except for one woman 
with dysmenorrhea, all patients received a hysteroscopy and 
abrasion with histomorphological analysis. All cases showed 
benign results. Low HE4 values in the subgroup of benign 
gynecological diseases were observed for endometriosis, 
followed by benign cervix diseases. Lowest concentrations 
of HE4 in women were observed in benign breast disorders 
(Table 1). 
 In men, all benign disease groups had higher median HE4 
values and broader ranges than healthy men and the corre-
sponding female disease group (Table 1). Similar to women, 
high values in benign gastrointestinal diseases were observed 
in liver cirrhosis and cholestasis. In benign urological dis-
eases, highest HE4 values were seen for uretheral calculus 
and prostatitis, in benign lung diseases for pneumonia and 
benign tumors. 
 Table  3 lists HE4 values of women and men with different 
malignant diseases. Highest HE4 concentrations in women 
were observed in ovarian cancer (p vs. benign gynecologi-
cal diseases:  < 0.0001). Signifi cantly higher values than in 
the respective organ-related control group of benign lung dis-
eases were also observed for lung cancer (p = 0.0001), as well 
as for borderline tumors (p = 0.008) and uterus corpus cancer 
(p = 0.001) as compared to the organ-related control group of 
benign gynecological diseases. Also, breast cancer patients 
showed higher HE4 concentrations than the respective organ-
related control group of benign breast diseases (p = 0.008). 
 Table 1  Distribution of HE4 in healthy controls and patients affected by benign diseases. 
Group Gender n Age, years HE4, pmol/L
Median Median Range Pctl95 p vs. healthy p vs. women
Healthy Females 109 38.4   40.4 10.0 – 111   72.0
Males   96 37.2   26.2 13.6 – 87.2   46.9  < 0.001
Benign lung disease Females   19 59.9   44.4 25.5 – 107   107   0.174
Males   31 59.3   57.1 20.3 – 237   170  < 0.001   0.089
Benign gastrointestinal 
disease
Females   44 54.1   36.5 16.4 – 424   289   0.941
Males   38 50.3   53.7 20.6 – 2366   989  < 0.001   0.003
Renal insuffi ciency Females   16 50.1 1042 53.4 – 2321 2321  < 0.001
Males   17 62.0 1368 28.4 – 7043 7043  < 0.001   0.048
Other benign urological 
disease
Females   6 62.5   34.3 25.9 – 50.4   50.4   0.225
Males   18 56.2   43.1 22.8 – 263   263  < 0.001   0.110
Benign prostate hyperplasia Males   21 70.3   48.4 24.2 – 710   235  < 0.001
Benign breast disease Females   48 44.9   31.7 16.4 – 81.1   63.7   0.002
Benign gynecological 
disease
Females 396 44.8   40.7 18.8 – 1178   94.6   0.297
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 Table  4 shows HE4 values in the different histological 
subgroups of ovarian cancer. The highest HE4 release was 
seen in the serous type (median 386 pmol/L, range 31.6 – 7507 
pmol/L) followed by the undifferentiated type (median 327.5, 
range 146 – 1009 pmol/L). Mucinous ovarian cancers had the 
lowest HE4 values (median 74.1, range 35.4 – 447 pmol/L). 
The group of others in Table 4 included fi ve solid, low differ-
entiated carcinomas of the ovary, three granulosa cell tumors, 
three malignant mixed m ü llerian tumors, one sarcoma of the 
ovary, one neuroendorendocrine tumor of the ovary and one 
clear cell carcinoma of the ovary. 
 Table 2  Distribution of HE4 in benign gynecological diseases. 
Diagnosis n Age, years HE4, pmol/L
Median Median Range Pctl5 Pctl95
Benign cervix dis. 36 37.5 38.8 22.1 – 177 24.8 125
Cystadenoma 78 54.2 42.8 20.4 – 145 27.5   94.6
Leiomyoma 66 43.1 39.3 20.1 – 1178 24.8 102
Bleeding disorder 32 51.1 43.4 25.2 – 112 26.8   82.3
Endometriosis 52 35.6 36.3 20.3 – 133 26.3   74.6
Functional ovarian cysts 84 44.8 41.1 18.8 – 194 24.2   88.0
Infl ammatory disease 10 44.0 67.6 39.9 – 120 39.9 120
Other benign gynecological 
diseases
38 46.6 38.7 26.6 – 277 27.7 130
 Table 3  Distribution of HE4 in patients affected by malignant diseases. 
Cancer Gender n Age, years HE4, pmol/L
Median Median Range Pctl95 p vs. 
healthy
p vs. 
women
Lung cancer Females   23 61.2   77.3 42.0 – 1529   710  < 0.001
Males   77 62.8   89.2 38.4 – 2126   322  < 0.001 0.594
Ear nose throat cancer Females   4 58.6   51.2 25.4 – 1780 1780   0.675
Males   26 58.7   68.4 30.5 – 229   146  < 0.001 0.542
Gastric cancer Females   24 67.2   46.2 27.0 – 523   288  < 0.001
Males   27 59.7   48.6 23.9 – 2482   126   0.018 0.756
Liver cancer Females   12 65.6   64.4 30.3 – 217   217  < 0.001
Males   27 66.0   62.0 28.6 – 439   299  < 0.001 0.952
Pancreatic cancer Females   20 63.6   42.9 25.0 – 146   134  < 0.001
Males   30 63.2   60.4 25.7 – 396   259  < 0.001 0.231
Colorectal cancer Females   21 62.6   47.0 27.2 – 112   96.7  < 0.001
Males   31 64.2   54.2 22.8 – 129   124   0.027 0.751
Esophagus/anal cancer Females   16 72.7   42.1 22.6 – 223   223  < 0.001
Males   19 63.5   66.1 25.7 – 1487 1487   0.423 0.094
Bladder cancer Females   9 70.3   67.8 34.7 – 484   484  < 0.001
Males   33 61.3   73.5 29.7 – 267   249   0.002 0.878
Renal cancer Females   16 66.3   40.6 22.2 – 185   185  < 0.001
Males   24 62.3   59.1 21.7 – 585   359   0.613 0.077
Prostate cancer Males   30 61.3   39.8 17.1 – 132   72.2   0.002
Breast cancer Females   50 53.1   37.2 22.5 – 483   172   0.996
Ovarian cancer Females 125 62.9 242 29.0 – 7507 2954  < 0.001
Borderline tumor Females   16 59.7   52.1 28.2 – 399   399   0.002
Cervix cancer Females   41 54.1   43.3 22.1 – 2412   138   0.110
Uterus corpus cancer Females   19 62.8   53.7 31.1 – 523   523  < 0.001
 Table 4  Distribution of HE4 in dependence of the histological type 
in ovarian cancer. 
Histology n Age, years HE4, pmol/L
Median Median Range Pctl5 Pctl95
Serous 84 62.9 386   31.6 – 7507   54.2 3124
Endometroid 12 63.2 165   39.7 – 3469   39.7 3469
Mucinous   8 67.7  74.1   35.4 – 447   35.4   447
Other 13 55.4  59.5   29.0 – 2301   29.0 2301
Undifferentiated   8 73.6 327 146 – 1009 146 1009
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 In men, the highest HE4 levels were seen in lung cancer 
(p vs. benign lung diseases 0.002) (Table 3). 
 Figure  2 illustrates high HE4 values separately for sex and 
age groups. With the exception of women over 50, where the 
highest values were seen for ovarian cancer, patients with renal 
failure generally reached highest HE4 levels. Apart from renal 
insuffi ciency and ovarian cancer, in the group of young women 
high HE4 values were seen for one patient with lung cancer and 
nine patients with benign gynecological, gastrointestinal and 
lung diseases. In this group of patients, women with myoma 
and cholangitis reached the highest HE4 values (Figure 2A). 
In women over 50 years of age 28 patients with carcinoma (6 
gynecological, 8 gastrointestinal, 5 lung, 5 breast and 4 other) 
 Table 5  Sensitivity of HE4 ARCHITECT at 95 % specifi city and AUC values with lower confi dence limits (LCL) and upper confi dence limits 
(UCL) in the differentiation of benign and malignant diseases. 
Cancer Control Gender ND NC Sensitivity,  % AUC (LCL  – UCL),  % p-Value
Lung cancer Benign lung disease Females   23   19 26.1 84.7 (72.8 – 96.5)  < 0.001
Males   77   31 11.7 68.9 (56.8 – 80.9   0.002
Breast cancer Benign breast disease Females   50   48 18.0 65.7 (54.9 – 76.5)   0.005
Ovarian cancer/Borderline 
tumor
Benign gynecological 
disease
Females 141 396 67.4 88.9 (85.3 – 92.5)  < 0.001
Uterus corpus cancer Benign gynecological 
disease
Females   19 396 21.1 72.1 (60.8 – 83.4)  < 0.001
Ovarian cancer/borderline 
tumor
Healthy and all other 
benign and malignant 
diseases
Females 141 893 55.3 86.2 (82.6 – 89.8)  < 0.001
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 Figure 2  Extreme values of HE4 for women (A) and men (B). 
 The upper curve is related to patients aged  ≥ 50 years, the lower 
curve to patients under 50 years. 
and also 12 patients with benign gynecological and gastroin-
testinal diseases showed extremely high HE4 values. This was 
mainly caused by patients with myoma and liver cirrhosis. 
 As in women, also in the older age group of men malig-
nant diseases showed high HE4 values (31 lung cancers, 22 
gastrointestinal cancers, and 24 other cancers), whereas in 
the younger age group highest values were observed in liver 
cirrhosis. 
 Table  5 shows AUCs and sensitivities of HE4 at for malig-
nant diseases 95 % specifi city in women and men. A signifi -
cant difference in HE4 values is detected compared to the 
respective benign disease. The largest area under the curve 
of HE4 in women was seen for the differentiation of ovarian 
cancer and borderline tumors from benign gynecological dis-
eases, amounting to 88.9 % . Even if healthy individuals and 
all benign and malignant diseases except ovarian cancer and 
borderline tumors served as one control group as compared 
to ovarian cancer and borderline tumors as disease group, the 
sensitivity of HE4 was still 55.3 % at 95 % specifi city and the 
corresponding AUC reached 86.2 % (Figure  3 ). 
 In men, only lung cancer showed signifi cantly higher HE4 
values than benign lung diseases with an AUC of 68.9 % and 
a sensitivity of 11.7 % (Table 5). 
 Discussion 
 Ovarian cancer is often detected at an advanced stage and thus 
ranks as the fi fth most common cause of death in women  (17) . 
Besides vaginal sonography, tumor marker values may aid to 
detect ovarian cancer in early stages. For almost 30 years, the 
tumor marker CA 125 was the most relevant biomarker for the 
management of patients with ovarian cancer  (18) . However, 
for the purpose of primary diagnosis, in clinical practice cor-
responding to the differential diagnosis of pelvic masses, the 
use of CA 125 has its limitations. The reason is not a lack of 
sensitivity of CA 125 for ovarian cancer, but the varying indi-
vidual baseline values of CA 125 in healthy women. The lack 
of specifi city is caused by frequently increased levels of CA 
125 in benign gynecological diseases such as endometriosis, 
fi bromas, uterine myomas, acute salpingitis and pelvic infl am-
matory diseases  (19) . In addition, several non-gynecological 
malignant diseases like lymphoma, lung cancer, breast cancer 
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and gastrointestinal cancers may release CA 125 as well as 
benign diseases affecting the serous membranes of the peri-
toneum (liver cirrhosis, chronic active hepatitis, pancreatitis), 
pleura or pericardium  (2, 19) . Therefore, further biomarkers 
are needed for the early detection and differential diagnosis 
of ovarian cancer. HE4 is one of the latest, most promising 
biomarkers in this fi eld  (5) . First studies concerning HE4 in 
blood indicate this protein to be frequently released by ovar-
ian cancer. In addition, HE4 offers a superior specifi city in 
benign gynecological diseases as compared to CA 125  (11, 
20, 21) . In literature, the combination of both biomarkers has 
been shown an increased specifi city and sensitivity in the dif-
ferential diagnosis of pelvic masses  (7, 8, 13 – 16) . 
 As systemic blood serum levels are not related to a spe-
cifi c organ in contrary to clinical examination, medical imag-
ing or tissue analysis, it is important to investigate the level 
of HE4 in the blood of healthy individuals and especially in 
patients with any non-gynecological benign diseases or other 
malignant diseases besides ovarian cancer. Our investigation 
considers women and men, in order to be able to observe hor-
monal relations and potentially clinically relevant releases in 
any other cancer. 
 Our fi rst obvious fi nding was the dependency of HE4 val-
ues from gender and age. In healthy individuals, HE4 values 
for men (median 26.2 pmol/L) were clearly lower than val-
ues for women (median 40.4 pmol/L). In both sexes, the HE4 
level increased with age. In regard to this fi nding, age and 
gender specifi c reference ranges will have to be considered. 
 In benign diseases, highest HE4 values for both sexes 
were seen in patients with renal failure (women, median 1042 
pmol/L; men, median 1368 pmol/L). This result is similar to 
other biomarkers like ProGRP or SCCA and was also described 
recently by Escudero 2011 for HE4  (12) . As a consequence, 
HE4 should not be used in patients with renal insuffi ciency or 
patients with abnormal serum creatinine levels. This fi nding can 
especially become relevant in patients receiving nephrotoxic 
chemotherapy who may develop renal disorders over time. 
 The majority of benign gastrointestinal diseases were not 
associated with an increase of HE4, which is different from the 
experience with CA 125. Nevertheless, especially in patients 
with liver cirrhosis and especially in men, HE4 reached high 
serum values up to 2000 pmol/L. However, liver cirrhosis is 
not frequent in women and therefore rarely problematic in the 
differential diagnosis of ovarian cancer. Patients with chronic 
disease like liver cirrhosis frequently show higher biomarker 
levels for HE4 as it is also known for  α -fetoprotein (AFP), 
CA 125, carcinoembryonic antigen (CEA) and CA 19-9 due 
to the impaired liver metabolism. 
 Somewhat higher HE4 values (up to 230 pmol/L) are also 
being observed in benign lung diseases, especially in men. 
This release arises most probably from the physiological 
expression of HE4 in the trachea, salivary glands and pulmo-
nary tissue as described earlier. 
 In the analysis of the different benign gynecological dis-
eases, HE4 values for women with endometriosis were in the 
range of healthy women (median 36.3 pmol/L). This is an 
important fi nding since endometriosis frequently entails high 
levels of CA 125  (10, 22) . If the analysis of HE4 in these 
patients shows low values, malignancy is unlikely. 
 In our study, we observed the highest release of HE4 among 
malignant diseases in ovarian cancer (median 242 pmol/L, 
maximum 7507 pmol/L). The histological subtypes of ovar-
ian cancer showed a varying HE4 release which was highest 
in the serous subtype (median 386 pmol/L, range 31.6 – 7507 
pmol/L) and lowest in the mucinous subtype (median 74.1 
pmol/L, range 35.4 – 447 pmol/L). Our data are consistent with 
the oligonucleotide microarray analysis of HE4 in malignant 
ovarian tissue by Drapkin et al.  (5) and Galgano et al.  (4) . In 
those studies the highest staining for HE4 was seen in serous 
ovarian carcinomas, whereas mucinous ovarian carcinomas 
showed negative staining for HE4. This high release in serous 
ovarian cancer and only slightly increased release in muci-
nous ovarian cancer is also known for CA 125. Thus, both 
biomarkers do not offer a relevant diagnostic capacity for 
mucinous ovarian cancer, neither alone or in combination. 
 With 77 pmol/L for women and 89 pmol/L for men, the 
second highest median HE4 values in women and men among 
the malignant diseases were seen in lung cancer patients. 
However, the sensitivity for the differentiation of lung cancer 
from benign lung disease was low in both sexes (women 26 % , 
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Figure 3 ROC curve  for HE4 ARCHITECT in women.
(A) Ovarian cancer and borderline tumor of the ovary vs. benign gynecological diseases. (B) Ovarian cancer and borderline tumor of the ovary 
vs. all other diseases. 
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men 12 % ). Nevertheless, it remains to be analyzed whether this 
release of HE4 in lung cancer patients is potentially additive to 
the established biomarkers CEA, Serum Cytokeratin Fragment 
(CYFRA) 21-1, SCCA, ProGRP and Neuron Specifi c Enolase 
(NSE). In elderly women and men, a broad variety of malig-
nant tumor diseases lead to clearly elevated HE4 levels. In con-
trast younger women (apart from ovarian cancer) and men with 
benign diseases present with low HE4 values. 
 In summary, our data confi rm HE4 in blood as a non-tumor 
specifi c and non-organ specifi c biomarker. Our results also 
confi rm by far the highest release of this protein in ovarian 
cancer if patients with renal failure are excluded from the 
investigation. 
 The AUC of HE4 in women in the differentiation of ovar-
ian cancer and borderline tumors from healthy individuals 
and all patients affected by other benign and malignant dis-
eases was very high, amounting to 86.2 % . Almost the same 
area under the curve was observed in the study of Escudero 
et al. (86.6 % )  (12) . As a consequence, very high HE4 levels 
are able to confi rm the diagnosis of ovarian cancer. 
 Especially in clinical differential diagnosis of ovar-
ian masses, it is of interest as to whether the early ovarian 
tumor stages International Federation of Gynecologists 
and Obstetricians (FIGO) I and II are present with elevated 
HE4 values. In younger women ( < 50 years), the patients 
with ovarian cancer FIGO II had the highest HE4 value. All 
other ovarian cancer patients with extremely high values in 
this age group had ovarian cancer stage FIGO III. In elderly 
women ( > 50 years), nine women with very high HE4 values 
presented with stage FIGO I, and also nine with FIGO stage 
II. Among 60 of these female patients  > 50 years, only two 
showed HE4 values  > 300 pmol/L and suffered from a benign 
disease. All other cases were cancer patients, among them 51 
with ovarian cancer. 
 Ovarian cancer patients who present with clinical symp-
toms are frequently diagnosed with late stage disease. Since 
early tumor stage is associated with a better prognosis in 
ovarian cancer patients, detection at an early tumor stage is 
crucial. Due to the high specifi city of this biomarker for ovar-
ian cancer and the high prevalence of elevated HE4 in early 
stage of this disease, it gives rise to the hope that HE4 can 
be helpful to detect ovarian cancer in an asymptomatic, early 
tumor stage. 
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